<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04585672</url>
  </required_header>
  <id_info>
    <org_study_id>1-16-02-297-20</org_study_id>
    <nct_id>NCT04585672</nct_id>
  </id_info>
  <brief_title>Ammonia Metabolism Assessed by Ammonia Infusion</brief_title>
  <acronym>NH4 inf</acronym>
  <official_title>Ammonia Metabolism Assessed by Ammonia Infusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study will develop a method to assess ammonia metabolism by ammonia infusion and&#xD;
      investigate ammonia production and clearance in healthy individuals and in patients with&#xD;
      liver cirrhosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 19, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of clearance (L/min) and production (micromol/min) of ammonia</measure>
    <time_frame>2 years</time_frame>
    <description>A physiological parameter</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in clearance (L/min) and production (micromol/min) of ammonia when measured while on ammonia modulating agents</measure>
    <time_frame>2 years</time_frame>
    <description>Proof of concept</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Ammonia; Metabolic Disorder</condition>
  <condition>Liver Failure, Chronic</condition>
  <arm_group>
    <arm_group_label>Healthy and Cirrhosis</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Ammonia infusion with and without ammonia targeting</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ammonia infusion</intervention_name>
    <description>Ammonia metabolism investigated in healthy individuals and patients with cirrhosis with and without ammonia lowering agent: glycerolphenylbutyrat (healthy) and Lactulose + Rifaximin (Cirrhosis)</description>
    <arm_group_label>Healthy and Cirrhosis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria - Healthy controls:&#xD;
&#xD;
          -  Alcohol &lt; 40g/day&#xD;
&#xD;
          -  BMI &lt; 30&#xD;
&#xD;
          -  Diseased or medicated&#xD;
&#xD;
        Inclusion Criteria - Patients with cirrhosis:&#xD;
&#xD;
          -  Child-Pugh A or B cirrhosis&#xD;
&#xD;
          -  BMI &lt; 30&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Child-Pugh score C&#xD;
&#xD;
          -  Kidney failure (eGFR &lt; 60 mL/min/1.73m2)&#xD;
&#xD;
          -  Overt hepatic encephalopathy or more than one previous 1 episode of overt hepatic&#xD;
             encephalopathy&#xD;
&#xD;
          -  Acute bacterial infection&#xD;
&#xD;
          -  Cancer&#xD;
&#xD;
          -  Diabetes&#xD;
&#xD;
          -  Ammonia-targeted treatment of hepatic encephalopathy other than lactulose (including&#xD;
             Rifaximin and branched-chain amino acids)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Peter Lykke Eriksen, MD PhD</last_name>
    <phone>+45 23715703</phone>
    <email>ple@clin.au.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Hepatology &amp; Gastroenterology</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Fagerlund</last_name>
      <phone>+45 23715703</phone>
      <email>mf@clin.au.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>September 23, 2020</study_first_submitted>
  <study_first_submitted_qc>October 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2020</study_first_posted>
  <last_update_submitted>October 12, 2020</last_update_submitted>
  <last_update_submitted_qc>October 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>End Stage Liver Disease</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

